Edition:
United States

TherapeuticsMD Inc (TXMD.A)

TXMD.A on American Stock Exchange

6.61USD
23 Mar 2017
Change (% chg)

$0.19 (+2.96%)
Prev Close
$6.42
Open
$6.41
Day's High
$6.85
Day's Low
$6.37
Volume
212,059
Avg. Vol
250,704
52-wk High
$9.28
52-wk Low
$4.39

Latest Key Developments (Source: Significant Developments)

Therapeuticsmd reports Q4 loss per share $0.12
Thursday, 23 Feb 2017 06:45am EST 

TherapeuticsMD Inc : TherapeuticsMD announces fourth quarter and full-year 2016 financial results . Q4 loss per share $0.12 . Q4 revenue $4.5 million versus $5.6 million . Q4 revenue view $5.9 million -- Thomson Reuters I/B/E/S . Q4 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S .TherapeuticsMD - pipeline of 2 late-stage product candidates advancing towards commercialization,launch of tx-004hr expected in Q4 pending regulatory approval.  Full Article

Franklin Resources reports 5.7 pct passive stake in TherapeuticsMD as of Dec. 31, 2016 - SEC filing
Tuesday, 7 Feb 2017 03:27pm EST 

:Franklin Resources, Inc reports 5.7 percent passive stake in TherapeuticsMD Inc as of Dec. 31, 2016 - SEC filing.  Full Article

TherapeuticsMD reports positive top-line results from pivotal phase 3 replenish trial in postmenopausal women with moderate to severe vasomotor symptoms (vms) treated with tx-001hr
Monday, 5 Dec 2016 04:05pm EST 

Therapeuticsmd Inc : TherapeuticsMD announces positive top-line results from pivotal phase 3 replenish trial in postmenopausal women with moderate to severe vasomotor symptoms (vms) treated with tx-001hr . To submit new drug application for tx-001hr to food and drug administration as early as q3 of 2017 . Very low reported incidence of adverse events of somnolence with tx-001hr .Additional efficacy and safety analyses of replenish trial data are ongoing.  Full Article

TherapeuticsMD announces Q3 2016 financial results
Thursday, 3 Nov 2016 04:05pm EDT 

TherapeuticsMD Inc : Qtrly revenues, net $ 5.5 million versus $ 5.2 million . TherapeuticsMD announces third quarter 2016 financial results . Q3 loss per share $0.13 .Q3 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.  Full Article

Therapeuticsmd reports Q2 loss per share $0.11
Thursday, 4 Aug 2016 04:05pm EDT 

Therapeuticsmd Inc : Therapeuticsmd announces second quarter 2016 financial results . Q2 loss per share $0.11 . Q2 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S .Topline phase 3 data for tx-001hr replenish trial on track for q4 of 2016.  Full Article

TherapeuticsMD, Inc announces pricing of common stock offering
Thursday, 7 Jan 2016 06:45am EST 

TherapeuticsMD, Inc:Announces pricing of $125 million common stock offering.Says public offering priced at $8.25 per share.  Full Article

TherapeuticsMD Announces $125 Million Offering of Common Stock
Tuesday, 5 Jan 2016 04:00pm EST 

TherapeuticsMD, Inc:Says launch of an underwritten public offering of $125 million of shares of its common stock.expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock.All of the shares in the offering are to be sold by TherapeuticsMD.The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Goldman, Sachs & Co. and Cowen and Company are acting as joint bookrunning managers for the offering.Stifel is acting as joint lead manager for the offering and Guggenheim Securities is acting as co-manager for the offering.intends to use a majority of the proceeds of the offering to fund commercialization activities for TX-004HR, its applicator-free vaginal estradiol softgel drug candidate, for other research, clinical trials, clinical formulation and development and for working capital and general corporate purposes.  Full Article

TherapeuticsMD announces positive top-line results from its phase 3 rejoice trial in postmenopausal women with vulvar and vaginal atrophy (vva) treated with 25 mcg, 10 mcg or 4 mcg of tx-004hr
Monday, 7 Dec 2015 04:10pm EST 

TherapeuticsMD:Says positive top-line results from its pivotal Phase 3 Rejoice Trial of TX-004HR, an investigational, applicator-free vaginal estradiol softgel.Says this is for treatment of moderate to severe dyspareunia (vaginal pain during sexual intercourse), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.  Full Article

TherapeuticsMD Receives Patent Allowance for VVA Candidate TX-004HR
Wednesday, 5 Aug 2015 07:30am EDT 

TherapeuticsMD Inc:Announces that the U.S. Patent and Trademark Office allowed patent application 14/136,048 related to TX-004HR, the company's phase 3 drug candidate for the treatment of vulvar and vaginal atrophy (VVA), which utilizes the company's SYMBODA(tm) technology.  Full Article

TherapeuticsMD announces pricing of common stock offering
Thursday, 9 Jul 2015 09:27pm EDT 

TherapeuticsMD Inc:Announces the pricing of an underwritten public offering of about 3.8 million shares of its common stock, offered at a price of $7.80 per share.Says the gross proceeds to TherapeuticsMD from this offering are expected to be about $30.0 million, before deducting underwriting discounts, commissions and other offering expenses payable by TherapeuticsMD.Says it has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to about 577,000 additional shares of common stock to cover over-allotments, if any.Says all of the shares in the offering are to be sold by TherapeuticsMD.Says the offering is expected to close on or about July 15, subject to the satisfaction of customary closing conditions.  Full Article

More From Around the Web

BRIEF-Therapeuticsmd reports Q4 loss per share $0.12

* TherapeuticsMD announces fourth quarter and full-year 2016 financial results